Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-04-20
DOI
10.1002/cpt.2911
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
- (2021) Antoine Italiano et al. INVESTIGATIONAL NEW DRUGS
- Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
- (2021) Apostolia-Maria Tsimberidou et al. Journal of Hematology & Oncology
- A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
- (2020) Xiaoyu Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
- (2020) Kyriakos P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective
- (2020) Arian Emami Riedmaier et al. AAPS Journal
- First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
- (2020) Malaka Ameratunga et al. BRITISH JOURNAL OF CANCER
- A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
- (2018) Diane A. J. van der Biessen et al. INVESTIGATIONAL NEW DRUGS
- A Phase 1 Study of Alpelisib (BYL719), an α- Specific PI3K Inhibitor, in Japanese Patients with Advanced Solid Tumors
- (2018) Yuichi Ando et al. CANCER SCIENCE
- Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology
- (2018) Mark Farha et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
- (2017) Janice M. Mehnert et al. INVESTIGATIONAL NEW DRUGS
- Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs
- (2016) J. M. Bullock et al. CLINICAL CANCER RESEARCH
- Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase
- (2015) N. Isambert et al. ANNALS OF ONCOLOGY
- Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
- (2014) Mark A. Dickson et al. INVESTIGATIONAL NEW DRUGS
- PBPK models for the prediction of in vivo performance of oral dosage forms
- (2013) Edmund S. Kostewicz et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Phase I Study of E7820, an Oral Inhibitor of Integrin -2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies
- (2011) M. Mita et al. CLINICAL CANCER RESEARCH
- Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products
- (2010) S. P. Kang et al. CLINICAL CANCER RESEARCH
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers
- (2009) Nancy L. Lewis et al. JOURNAL OF CLINICAL ONCOLOGY
- A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state
- (2008) C. L. O’Bryant et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ‘No risk, no fun’: Challenges for the oncology phase I clinical trial time-performance
- (2008) Jaap Verweij EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now